Facts and figures23 Jun 2019 10:07
Was it last weekend or maybe one before we had a little discussion on this well here is an article that gives a clearer picture on the facts and figures of CI therapies that already have a huge market that is only going to get bigger...$50 billion a year by 2025 is the often given figure...
'Researchers divided the number of deaths from cancers for which a checkpoint inhibitor had been FDA approved by the total number of cancer deaths to determine the proportion of people eligible for checkpoint inhibitor therapy. They estimated the number of people who could benefit from checkpoint inhibitors by multiplying the number of people estimated to be eligible for each cancer type by the overall response rate reported on the FDA drug label for each year a specific indication was approved.
The results showed that six checkpoint inhibitors received FDA approval for 14 indications between March 25, 2011, and Aug. 17, 2018.
The investigators found that the estimated percentage of patients with cancer eligible for treatment with checkpoint inhibitors increased markedly over the study period, starting at 1.54% (95% CI, 1.51-1.57) in 2011 and increasing to 26.86% (95% CI, 26.75-26.98) in 2015 and 43.63% (95% CI, 43.51-43.75) in 2018.
The estimated response rate was 0.14% (95% CI, 0.13-0.15) in 2011 and increased to 5.86% (95% CI, 5.8-5.92) by 2015 as additional checkpoint inhibitors were approved for more indications. The estimated percentage of responders reached 12.46% (95% CI, 12.37-12.54) by 2018.'
So basically.....' fewer than 13% of patients with cancer respond to checkpoint inhibitors.'
Sobering
https://www.healio.com/hematology-oncology/melanoma-skin-cancer/news/online/%7Be4a4f7a1-af35-4be7-a1a0-0fa75a826206%7D/low-response-rate-for-checkpoint-inhibitors-underscores-unrealistic-expectations-about-their-effectiveness
Sign In
Follow the stocks
